ClinicalTrials.gg
Not yet recruitingNCT07941765SAGE UTIUpdated Nov 17, 2026

Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults

An observational study in UTI, Recurrent UTIs and UTI - Urinary Tract Infection, sponsored by Pathnostics. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pathnostics · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,000
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.

The main question this trial aims to answer is:

Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?

Participants will:

  • Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
  • Provide a urine sample during their initial clinic visit.
  • Complete questionnaires at the initial visit and approximately 14 and 28 days later.

Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.

Read the detailed description

**Background and Rationale**

Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.

Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.

**Trial Design**

SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.

Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:

  • **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
  • **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.

**Trial Procedures**

Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.

Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.

Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.

**Clinical Significance**

The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.

02

Conditions studied

  • UTI
  • Recurrent UTIs
  • UTI - Urinary Tract Infection
  • UTI - Lower Urinary Tract Infection

Keywords

  • Urinary Tract Infection (UTI)
  • Recurrent Urinary Tract Infection (rUTI)
  • Guidance UTI
  • Standard Urine Culture
  • Pooled Antibiotic Susceptibility Testing (P-AST)
  • Antibiotic Resistance
  • Older Adults
03

In context

Urinary Tract Infections

806 studies on the registry are indexed under Urinary Tract Infections; 134 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 241 across 199 observational studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

Pathnostics is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice

Eligibility criteria

nclusion Criteria:

  • Able to provide written
  • Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
  • A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
  • Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
  • Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
  • Management requires microbial identification and antibiotic sensitivities from urine
  • Able to provide a urine specimen (midstream voided or catheter collected)

Exclusion Criteria:

  • Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
  • Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
  • Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate or surgery in previous 30 days)
  • Currently receiving radiation therapy in the pelvic region
  • Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
  • Subjects with history of bladder in the past 3 years
  • Subjects that have been treated with chemotherapy in the past 3 years
  • Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
  • Incarceration
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Arm A - Guidance UTI

    Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.

  • Arm B - Standard Urine Culture:

    Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Percent difference between diagnostic test arm in the number of composite negative outcomes

    Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis)

    Time frame: 28 days

Secondary outcomes

  1. Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed

    Percent difference between diagnostic test arm in: * The number of adverse events * The number of subjects empirically treated * The number of changes to antibiotic(s) prescribed

    Time frame: 28 days

  2. Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject

    Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject

    Time frame: 28 days

  3. Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)

    Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)

    Time frame: 28 days

  4. Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions

    Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions

    Time frame: 28 days

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 84 observational studies under Urinary Tract Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 17, 2026
StartEst.
Dec 14, 2026
Primary completionEst.
Dec 14, 2027
CompletionEst.
Dec 14, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941765
Lead sponsor
Pathnostics
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Dec 14, 2027 (estimated)
Completion
Dec 14, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Darshika Mistry
Contact
dmistry@pathnostics.com
6482844874

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion